Compare Jabil Inc (JBL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Revvity Inc — how do they compare? Jabil Inc trades at $319 (market cap $32.06B), while Revvity Inc trades at $110.1 (market cap $11.87B). The key difference: Jabil Inc is far larger — about 2.7× Revvity Inc's market cap, and Revvity Inc pays the higher dividend (0.26%). Which is the better fit depends on your goals.
| JBL | RVTY | |
|---|---|---|
Market Cap | $32.06B | $11.87B |
Sector | Technology | Technology |
52-Week High | $385.50 | $117.75 |
52-Week Low | $192.49 | $82.26 |
Enterprise Value | $34.59B | $14.36B |
Dividend Yield | 0.1% | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $305.91, up 1.63% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 50% analyst buy ratings and a $448.29 consensus price target, representing 46% upside potential. Recent news highlights AI infrastructure growth and new logistics hub expansion in Penang, while technical indicators show oversold conditions with RSI at 17.67.
The outlook remains positive with AI-driven revenue growth accelerating, though valuation at 38.29 P/E appears stretched. Key risks include competitive pressures in EMS sector and execution challenges in scaling AI manufacturing capacity. The stock offers growth exposure to AI infrastructure boom but requires monitoring of margin sustainability.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
